| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:SRI-29329
CAS:2086809-58-5
Purity:≥98% Package:100mg 1g,5g,根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:SRI-29329;Cyclin dependent kinase,inhibit,SRI29329,SRI-29329,Inhibitor,SRI 29329,CDK
CAS:2086809-58-5
Purity:99.49% Package:1 mg;10 mg;100 mg;25 mg;5 mg;50 mg
|
| Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
| Tel: |
021-59167510 18117107507 |
| Email: |
vip@med-life.cn |
| Products Intro: |
Product Name:SRI-29329
CAS:2086809-58-5
Purity:>=99% Package:5mg;25mg;200mg;10mg;100mg;50mg;10mM*1mLinDMSO
|
| Company Name: |
RD International Technology Co., Limited
|
| Tel: |
18024082417 |
| Email: |
market@ubiochem.com |
| Products Intro: |
Product Name:SRI-29329
CAS:2086809-58-5
Purity:5mg;10mg;50mg;100mg;250mg;500mg;1g Package:5mg;10mg;50mg;100mg;250mg;500mg;1g
|
|
| | SRI-29329 Basic information |
| Product Name: | SRI-29329 | | Synonyms: | SRI-29329;9H-Purine-2,6-diamine, N2-[(1S,2S)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-(1-methylethyl)-;Cyclin dependent kinase,inhibit,SRI29329,SRI-29329,Inhibitor,SRI 29329,CDK | | CAS: | 2086809-58-5 | | MF: | C20H26ClN7 | | MW: | 399.92 | | EINECS: | | | Product Categories: | | | Mol File: | 2086809-58-5.mol |  |
| | SRI-29329 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (125.03 mM; Need ultrasonic) | | form | Solid | | color | White to off-white |
| | SRI-29329 Usage And Synthesis |
| Biological Activity | SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively[1].
SRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity[1]. | | References | [1]. Yihui Shi, et al. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. |
| | SRI-29329 Preparation Products And Raw materials |
|